Department of Immunotechnology, CREATE Health Translational Cancer Center, Medicon Village (Bldg 406), Lund University, 223 81 Lund, Sweden.
Nat Rev Cancer. 2017 Mar;17(3):199-204. doi: 10.1038/nrc.2016.153. Epub 2017 Feb 3.
Interest in precision diagnostics has been fuelled by the concept that early detection of cancer would benefit patients; that is, if detected early, more tumours should be resectable and treatment more efficacious. Serum contains massive amounts of potentially diagnostic information, and affinity proteomics has risen as an accurate approach to decipher this, to generate actionable information that should result in more precise and evidence-based options to manage cancer. To achieve this, we need to move from single to multiplex biomarkers, a so-called signature, that can provide significantly increased diagnostic accuracy. This Opinion article focuses on the progress being made in identifying protein biomarker signatures of clinical utility, using blood-based proteomics.
人们对精准诊断学的兴趣源于这样一种理念，即癌症的早期检测将使患者受益；也就是说，如果早期发现，更多的肿瘤应该可以切除，治疗效果也会更好。血清中含有大量潜在的诊断信息，亲和蛋白质组学已经成为一种准确的方法来解读这些信息，从而生成可行的信息，这应该会带来更精确和基于证据的癌症管理选择。为了实现这一目标，我们需要从单一生物标志物转向多重生物标志物，即所谓的“特征”，它可以提供显著提高的诊断准确性。本文观点集中在使用基于血液的蛋白质组学来鉴定具有临床应用价值的蛋白质生物标志物特征方面所取得的进展。
